PATENT COOPERATION TREAT

PCT

REC'D Y	2	6	SEP	2005
WIPO				PCT
		_		

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

(Chapter II of the Patent Cooperation Treaty)

(PCT Article 36 and Rule 70)

A 11 11 11					
Applicant's or agent's PC/4-33452A	file reference	FOR FURTHER	ACTION	See Form PCT/IPEA/416	
International application No. PCT/EP2004/012386		International filing da 02.11.2004	te (day/month/year)	Priority date (day/month/year) 03.11.2003	
International Patent C	assification (IPC) or na	ational classification an	1 IDC		
A61K31/41, A61K A61P9/00, A61P9	31/4965, A61K31/		61P3/10, A61P5/00.	A61P5/18, A61P5/48, A61P5/50,	
Applicant NOVARTIS AG et	al.				
This report is t Authority unde	he international prel r Article 35 and tran	iminary examination	report, established by	this International Preliminary Examining	
1	Authority under Article 35 and transmitted to the applicant according to Article 36. This REPORT consists of a total of 5 sheets, including this cover sheet.				
		ANNEXES, compris		·	
			_	s, as follows:	
 a. sent to the applicant and to the International Bureau) a total of sheets, as follows: sheets of the description, claims and/or drawings which have been amended and are the basis of this report and/or sheets containing rectifications authorized by this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions). 					
l Dey	sheets which supersede earlier sheets, but which this Authority considers contain an amendment that goes beyond the disclosure in the international application as filed, as indicated in item 4 of Box No. I and the Supplemental Box.				
b. (sent to the International Bureau only) a total of (indicate type and number of electronic carrier(s)), containing a sequence listing and/or tables related thereto, in computer readable form only, as indicated in the Supplemental Box Relating to Sequence Listing (see Section 802 of the Administrative Instructions).					
4. This report con	tains indications rela	ting to the following	items:		
☑ Box No. I	Basis of the opinion	on			
☐ Box No. II	Priority .				
🖾 Box No. III	Non-establishmer	nt of opinion with reg	ard to novelty, inventive	e step and industrial applicability	
☐ Box No. IV	Lack of unity of in		•	, and applicating	
⊠ Box No. V	Reasoned statem applicability; citati	ent under Article 35(ons and explanation	2) with regard to noveli s supporting such state	ty, inventive step or industrial ement	
☐ Box No. VI	Certain document	s cited			
☐ Box No. VII		the international app			
☐ Box No. VIII	Certain observation	ons on the internation	al application		
Date of submission of th	e demand		Date of completion of the	his report	
30.06.2005		23.09.2005			
Name and mailing address of the international preliminary examining authority:			Authorized Officer		
D-80298 M Tel. +49 8	Patent Office	epmu d	Taylor, G.M.	2399-	
			110, 743 03 2	Other carles	

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/012386

_							
_	Box No. I	Basis of the report					
1	. With regard filed, unless	With regard to the language, this report is based on the international application in the language in which it was filed, unless otherwise indicated under this item.					
	wnich i D inter D publ	report is based on translations from the original language into the following lang in is the language of a translation furnished for the purposes of: ternational search (under Rules 12.3 and 23.1(b)) sublication of the international application (under Rule 12.4) ternational preliminary examination (under Rules 55.2 and/or 55.3)	uage ,				
2	Have Deell I	With regard to the elements* of the international application, this report is based on (replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report):					
	Description,	n, Pages					
	1-24	as originally filed					
	Claims, Num	mbers					
	1-7	as originally filed					
	□ a seque	uence listing and/or any related table(s) - see Supplemental Box Relating to Sec	quence Listing				
з.	☐ the d☐ the d☐ the d☐ the d☐	mendments have resulted in the cancellation of: description, pages claims, Nos. drawings, sheets/figs sequence listing (specify): table(s) related to sequence listing (specify):					
4.	Supplements the di the cl the di the di	eport has been established as if (some of) the amendments annexed to this report made, since they have been considered to go beyond the disclosure as filed stal Box (Rule 70.2(c)). description, pages claims, Nos. drawings, sheets/figs sequence listing (specify): table(s) related to sequence listing (specify):	ort and listed below , as indicated in the				
		em 4 applies, some or all of these sheets may be marked "su	perseded."				

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/012386

_						
_		x No. III Non- plicability	establishment ————	of op	pinion with regard to novelty, inventive step and industrial	
1.	The	ne questions whether the claimed invention appears to be novel, to involve an inventive step (to be non- ovious), or to be industrially applicable have not been examined in respect of:				
		the entire international application,				
	Ø	claims Nos. 7				
		because:				
	×	the said international application, or the said claims Nos. 7 relate to the following subject matter which does not require an international preliminary examination (specify):				
		see separate sheet				
		the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):				
		the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.				
		no international search report has been established for the said claims Nos.				
		the nucleotide and/or amino acid sequence listing does not comply with the standard provided for in Annex C of the Administrative Instructions in that:				
		the written form	1		has not been furnished	
					does not comply with the standard	
		the computer re	adable form		has not been furnished	
					does not comply with the standard	
		the tables relate not comply with	ed to the nucleot the technical re	ide a quire	nd/or amino acid sequence listing, if in computer readable form only, doments provided for in Annex C-bis of the Administrative Instructions.	
١		See separate sh	neet for further d	letail	S .	

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY

International application No. PCT/EP2004/012386

Box No. V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes: Claims

1-7

1-6

No: Claims

Inventive step (IS)

Yes: Claims 1-7

No: Claims

Industrial applicability (IA)

Yes: Claims No: Claims

2. Citations and explanations (Rule 70.7):

see separate sheet

INTERNATIONAL PRELIMINARY REPORT ON PATENTABILITY (SEPARATE SHEET)

International application No.

PCT/EP2004/012386

Section III

 Claim 7 relates to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of this claim (Art. 34(4)(a)(I) PCT).

Section V

- 2. Having regard to the prior art cited in the International Search Report, the subject-matter of claims 1-7 meets the requirements of Art. 33(2) PCT.
- 3. An inventive step (Art. 33(3) PCT) can be acknowledged on the basis of the findings reported in the description page 4, line 4 to page 5, line 14.
- 4. Claims 1-6 meet the requirements of Art. 33(4) PCT.
- 5. For the assessment of the present claim 7 on the question whether it is industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.